Palbociclib Patent Expiration
Palbociclib is Used for treating HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. It was first introduced by Pfizer Inc
Palbociclib Patents
Given below is the list of patents protecting Palbociclib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ibrance |
US11065250 (Pediatric) | Solid Dosage Forms Of Palbociclib | Feb 19, 2037 | Pfizer |
| Ibrance | US11065250 | Solid dosage forms of palbociclib | Aug 19, 2036 | Pfizer |
| Ibrance |
US10723730 (Pediatric) | Solid Forms Of A Selective Cdk4/6 Inhibitor | Aug 08, 2034 | Pfizer |
| Ibrance | US10723730 | Solid forms of a selective CDK4/6 inhibitor | Feb 08, 2034 | Pfizer |
| Ibrance |
USRE47739 (Pediatric) | Sep 05, 2027 | Pfizer | |
| Ibrance | USRE47739 | 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones | Mar 05, 2027 | Pfizer |
| Ibrance | US6936612 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
Jan 16, 2023
(Expired) | Pfizer |
| Ibrance | US7208489 | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones |
Jan 16, 2023
(Expired) | Pfizer |
| Ibrance | US7456168 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones |
Jan 16, 2023
(Expired) | Pfizer |
Palbociclib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Palbociclib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
